Sanofi receives European approval for rheumatoid arthritis therapy Kevzara

Sanofi has announced that its rheumatoid arthritis therapy Kevzara has been approved by the European Commission.

The drug has been approved in combination with methotrexate for the treatment of moderate to severely active rheumatoid arthritis among adult patients who are unable to benefit from treatment with disease modifying anti-rheumatic drugs.

This approval was based on positive safety and efficacy data from seven phase III trials in the global SARIL-RA clinical development programme, which involved more than 3,300 patients.

Rheumatoid arthritis is one of the most common rheumatic conditions, affecting approximately 2.9 million people in Europe. There is a strong need for new treatment options, as many patients are unable to benefit from existing drugs.

Mary Dickens, country chair and general manager of general medicines at Sanofi in Ireland, said: "Despite a number of existing treatments, there are still patients in need of an effective alternative. Sarilumab presents an additional option for those people."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.